Canaccord Genuity analyst William Plovanic maintained a Hold rating on AngioDynamics (NASDAQ:ANGO) on Wednesday, setting a price target of $28, which is approximately 2.04% above the present share price of $27.44.
Plovanic expects AngioDynamics to post earnings per share (EPS) of -$0.09 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in AngioDynamics, with an average price target of $30.
The analysts price targets range from a high of $32 to a low of $28.
In its latest earnings report, released on 02/28/2021, the company reported a quarterly revenue of $71.18 million and a net profit of -$2.95 million. The company's market cap is $1.05 billion.
According to TipRanks.com, Canaccord Genuity analyst William Plovanic is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.0% and a 52.20% success rate.
AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.